Multiple Sclerosis Research Repository

1.  “A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives”:by Emanuele D’Amico

-However, preliminary results from a phase III trial of Natalizumab in patients with SPMS (ASCEND; NCT01416181) showed no efficacy in terms of delaying disability assessed by EDSS, Timed 25-Foot Walk, and 9-Hole Peg Test [101].

-Rituximab did not delay the disability progression compared to placebo.